NEW YORK, Jan. 18, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on RARE, REGN, SGEN, and SGMO which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com evaluates Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Regeneron Pharmaceuticals
Shares in Novato, California headquartered Ultragenyx Pharmaceutical Inc. jumped 4.28%, ending Wednesday's trading session at $47.77. The stock recorded a trading volume of 566,715 shares, which was higher than its three months average volume of 464,370 shares. The Company's shares have gained 8.52% in the last month. The stock is trading 0.20% above its 50-day moving average. Moreover, shares of Ultragenyx Pharma have a Relative Strength Index (RSI) of 49.98.
On January 04th, 2018, Ultragenyx Pharma announced an update to its development plan for UX007 in patients with long-chain fatty acid oxidation disorder. Following an end-of-phase-2 meeting with the FDA, the Company is working to provide additional information to submit for consideration of an early filing based on the results from the Phase-2 study. The Company is simultaneously completing the design of a Phase-3 study that could be used for registrational or confirmatory purposes. Get the full research report on RARE for free by clicking below at:
Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc.'s stock climbed 1.04%, closing the day at $374.07 with a total trading volume of 738,804 shares. The Company's shares have advanced 2.98% over the past year. The stock is trading 2.47% below its 50-day moving average. Additionally, shares of Regeneron Pharma have an RSI of 46.42.
On January 08th, 2018, Regeneron Pharma announced that the Company and Sanofi will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology, and the IL-4/IL-13 pathway-blocking antibody dupilumab in Type 2 allergic diseases. Under the terms of the expansion, the investment in cemiplimab will be increased to a minimum of $1.64 billion, an increase of approximately $1 billion over the initial 2015 agreement, and the duo will continue to equally fund cemiplimab development.
On January 09th, 2018, research firm Citigroup reiterated its 'Neutral' rating on the Company's stock with an increase of the target price from $380 a share to $388 a share. Access the free research report on REGN now by signing up at:
On Wednesday, shares in Bothell, Washington headquartered Seattle Genetics Inc. recorded a trading volume of 1.86 million shares, which was higher than their three months average volume of 938,950 shares. The stock ended the day 3.16% higher at $52.56. The Company's shares have advanced 1.43% in the past month. The stock is trading below its 50-day moving average by 6.68%. Furthermore, shares of Seattle Genetics have an RSI of 43.94.
On January 02nd, 2018, Seattle Genetics announced that the US FDA has accepted for filing a supplemental Biologics License Application for ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. The FDA granted Priority Review for the application, and the Prescription Drug User Fee Act target action date is May 01st, 2018. Are you already registered with Wall St. Equities? Do so now for free, and get the report on SGEN at:
Richmond, California headquartered Sangamo Therapeutics Inc.'s stock rose 1.16%, finishing yesterday's session at $17.50 with a total trading volume of 1.39 million shares. The Company's shares have advanced 6.71% in the last month, 17.85% in the previous three months, and 326.83% over the past year. The stock is trading above its 50-day and 200-day moving averages by 12.44% and 57.88%, respectively. Additionally, shares of Sangamo Therapeutics have an RSI of 55.95.
On January 03rd, 2018, Sangamo Therapeutics (SGMO) and Pfizer Inc. (PFE) announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene. Under the terms of the collaboration agreement, SGMO will be responsible for the development of ZFP-TF candidates; and PFE will be operationally and financially responsible for subsequent research, development, manufacturing, and commercialization for the C9ORF72 ZFP-TF program and any resulting products. Aspiring Member, please take a moment to register below for your free research report on SGMO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----ultragenyx-pharma-regeneron-pharma-seattle-genetics-and-sangamo-therapeutics-300584491.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...
Our kitchen and food has the best medicinal properties to fight stress. These are the top 10 foods ...View All